Background Endoscopic submucosal dissection (ESD) enables en bloc resection of early gastrointestinal cancers and provides ...

Compared to minimally invasive surgery, endoscopic submucosal dissection (ESD) represents an advanced, less-invasive endoscopic treatment for early gastrointestinal cancer. ESD has significant ...

Endoscopic submucosal dissection (ESD) represents a significant advance in therapeutic endoscopy with the major advantage being the ability to achieve a higher en bloc resection rate for early stage ...

Endoscopic submucosal dissection to remove large colorectal lesions was performed safely and successfully in an outpatient setting, based on data from more than 600 patients. The widespread adoption ...

For patients with large benign colonic lesions, endoscopic submucosal dissection (ESD) is associated with reduced recurrence at six months compared with endoscopic mucosal resection (EMR), according ...

Safety and efficacy of combining genotype-guided irinotecan (Iri) with 5FU, leucovorin (LV), oxaliplatin (Ox), and docetaxel (Tax) (gFOLFOXIRITAX): The I-FLOAT phase 1 dose-escalation study for ...

Malignant or premalignant changes in the oesophagus may take the form of either squamous cell carcinoma or adenocarcinoma, or their respective premalignant (dysplastic) forms. In the UK, approximately ...

Duodenal lesions (benign, dysplastic or neoplastic) are rare. Symptoms include nausea and vomiting, loss of appetite and weight, anaemia and abdominal pain. Lesions in people who have inherited ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--EndoClot Plus, Inc. (EPI), a privately held medical device company announced the FDA 510(k) clearance of EndoClot ® Submucosal Injection Agent (EndoClot ® SIA) ...